Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Acute Respiratory Distress Syndrome (ARDS) Clinical Trial

Official title: PUERTA: A P2A Multi-center, Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Efficacy of the eNAMPT Targeting mAb ALT-100 in Moderate/Severe ARDS/VILI Patients

Status Not yet recruiting

Clinical Trial Summary

A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.

Clinical Trial Description

PUERTA is a Phase 2a, randomized, double-blind, placebo-controlled study in adults with moderate to severe ARDS consequent to sepsis, septic shock, trauma, and/or bacterial or viral pneumonia who have been hospitalized. The safety and tolerability, PK, preliminary efficacy, and PD of a single infusion of ALT-100 mAb will be assessed. All participants will receive study drug within 12 hours of their ARDS diagnosis and within 4 hours of initiation of MV (mechanical ventilation). It is planned that 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of either ALT-100 mAb or placebo via IV infusion at the time the diagnosis of moderate to severe ARDS is confirmed. An additional 9 participants may be randomized if an optional cohort of low or intermediate ALT-100 mAb dose is enrolled. The study will be conducted in 2 parts: - Part A: a dose escalation phase followed by - Part B: dose expansion phase Dose Escalation (Part A) Part A will assess 2 doses of ALT-100 mAb in sequentially enrolled cohorts of up to 9 participants in each cohort. The planned doses of ALT-100 mAb are 0.4 mg/kg (Cohort 1a) and 1.0 mg/kg (Cohort 2a). Dose Expansion (Part B) Following SRC review of all data up to Day 29 from the 9 participants in each cohort in Part A, additional participants (up to 36 per dose cohort) may be enrolled into 2 dose expansion cohorts, the dose of which will be determined by the SRC. Part B will further explore the safety, preliminary efficacy, PK, and systemic biomarker profile of ALT-100 mAb. Participants enrolled in Part A may not be re-enrolled in Part B. The screening, Treatment, and Safety Follow-up schedules are the same for Part A (dose escalation) and Part B (dose expansion) cohorts. ;

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome (ARDS)
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

• NCT number: NCT05938036
• Study type: Interventional
• Source: Aqualung Therapeutics Corp.
• Contact: Stan Miele
• Phone: (919) 410-0504
• Email: stan@aqualungtherapeutics.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 14, 2024
• Completion date: December 31, 2024